Literature DB >> 17975491

Prognostic value of different metabolic measurements with fluorine-18 fluorodeoxyglucose positron emission tomography in resectable non-small cell lung cancer: a two-center study.

Wouter K de Jong1, Henricus F M van der Heijden, Jan Pruim, Otilia Dalesio, Wim J G Oyen, Harry J M Groen.   

Abstract

INTRODUCTION: Standard uptake value (SUV) is a quantitative measure for the preferential uptake of a radiopharmaceutical in a tumor compared with the homogeneous distribution in the body. SUV can be based on the maximal value of one pixel (SUVmax) or on the mean value in a region outlined by isodensity contours. The prognostic value of different SUVs in non-small cell lung cancer (NSCLC) is not established. We evaluated this value for SUVmax, SUV70%, and SUV50% among patients with resectable NSCLC.
METHODS: All consecutive patients with resectable NSCLC who underwent an attenuation-corrected whole-body fluorine-18 fluorodeoxyglucose positron emission tomography scan from two university hospitals were selected. By adjusting the isocontour in the region of interest on the scan, SUVmax, SUV70%, and SUV50% of the primary tumor were calculated.
RESULTS: Sixty-six patients (50 male, median age 63 years) were included. Of the tumors, 16 were pathological stage IA, 23 were IB, 4 were IIA, 14 were IIB, and 9 were IIIA. Median (range) values for SUVmax, SUV70%, and SUV50% were 6.4 (1.6-19.1), 5.1 (1.0-15.7), and 4.0 (0.9-13.4), respectively. SUVs were associated with survival. Analysis of residuals of SUVmax as a continuous variable in a Cox's proportional hazard model for survival suggested no cutoff point and no indication of time-dependency. Patients with a SUV higher than the median value had a worse survival than patients with a SUV lower than median (hazard ratios for SUVmax, SUV70%, and SUV50% all were 2.9; p = 0.02).
CONCLUSIONS: SUVmax, SUV70%, and SUV50% measured with fluorine-18 fluorodeoxyglucose positron emission tomography have a similar prognostic value, and no "natural" cutoff point for SUVmax in resectable NSCLC was identified.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17975491     DOI: 10.1097/JTO.0b013e31815608f5

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN: 1556-0864            Impact factor:   15.609


  5 in total

1.  The correlation of expression of VEGF and EGFR with SUV of (18)FDG-PET-CT in non-small cell lung cancer.

Authors:  Xiguang Liu; Hongjun Zhang; Xiaoyun Yu; Tingting Song; Peng Huang; Haichao Wang; Shan-Ai Song
Journal:  Contemp Oncol (Pozn)       Date:  2014-11-05

2.  Evaluation of elastix-based propagated align algorithm for VOI- and voxel-based analysis of longitudinal (18)F-FDG PET/CT data from patients with non-small cell lung cancer (NSCLC).

Authors:  Gerald Sma Kerner; Alexander Fischer; Michel Jb Koole; Jan Pruim; Harry Jm Groen
Journal:  EJNMMI Res       Date:  2015-03-21       Impact factor: 3.138

Review 3.  Prognostic value of 18F-FDG-PET/CT in patients with nasopharyngeal carcinoma: a systematic review and meta-analysis.

Authors:  Jie Lin; Guozhu Xie; Guixiang Liao; Baiyao Wang; Miaohong Yan; Hui Li; Yawei Yuan
Journal:  Oncotarget       Date:  2017-05-16

4.  Clinical outcome and predictors of survival and pneumonitis after stereotactic ablative radiotherapy for stage I non-small cell lung cancer.

Authors:  Joe Y Chang; Hui Liu; Peter Balter; Ritsuko Komaki; Zhongxing Liao; James Welsh; Reza J Mehran; Jack A Roth; Stephen G Swisher
Journal:  Radiat Oncol       Date:  2012-09-10       Impact factor: 3.481

5.  Correlations Between the EGFR Mutation Status and Clinicopathological Features of Clinical Stage I Lung Adenocarcinoma.

Authors:  Tetsuya Isaka; Tomoyuki Yokose; Hiroyuki Ito; Masashi Nagata; Hideyuki Furumoto; Teppei Nishii; Kayoko Katayama; Kouzo Yamada; Haruhiko Nakayama; Munetaka Masuda
Journal:  Medicine (Baltimore)       Date:  2015-10       Impact factor: 1.817

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.